MedTrace Logo

Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke

NCT07143786 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-08-27

No results posted yet for this study

Summary

A phase I/IIa clinical trial investigating the safety and preliminary efficacy of intravenous administration of human induced neural stem cell-derived exosomes for acute ischemic stroke

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

iNSC-EV01

Intravenous induced neural stem cell-derived exosome

DRUG

Placebo

iNSC-EV01 mimics

Sponsors & Collaborators

  • Wiseheart Co.Ltd

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-07-31
Completion
2027-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07143786 on ClinicalTrials.gov